Literature DB >> 17168752

The redox regulation of thiol dependent signaling pathways in cancer.

Gregory I Giles1.   

Abstract

Reactive oxygen species (ROS) play a central role as second messengers in many signal transduction pathways, where they can post-translationally modify proteins via the oxidation of redox sensitive cysteine residues. The range of cellular processes under redox regulation is extensive and includes both the proliferative and apoptotic pathways. Control of the cellular redox environment is therefore essential for normal physiological function and perturbations to this redox balance are characteristic of many pathological states. Oxidative stress is particularly prevalent in cancer, where many malignant cell types possess an abnormal redox metabolism involving down-regulation of antioxidant enzymes and impaired mitochondrial function. This provides a major opportunity to design therapeutic strategies to selectively target cancer cells based on their redox profile. This review will provide a background to this emerging field by summarizing the known redox biochemistry of ROS signaling. The mechanisms of ROS generation by the action of oxidoreductases and nitric oxide synthases will be discussed in conjunction with the cell's major antioxidant defenses, with special emphasis placed on the subcellular location of these redox reactions. The effect of ROS on proliferation and apoptosis will be examined by looking at interactions with transcription factors and the Akt, TNF and MAPK signaling pathways. The review will also outline the major differences in redox metabolism between cancer cells and their non-malignant counterparts. Although the full extent of the ROS regulation of signaling pathways is only beginning to be mapped, early indications are that this paradigm will provide new therapeutic targets for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17168752     DOI: 10.2174/138161206779010549

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  54 in total

1.  Novel cationic lipid that delivers siRNA and enhances therapeutic effect in lung cancer cells.

Authors:  Yunching Chen; Joyeeta Sen; Surendar Reddy Bathula; Qi Yang; Raffaella Fittipaldi; Leaf Huang
Journal:  Mol Pharm       Date:  2009 May-Jun       Impact factor: 4.939

Review 2.  Cellular redox pathways as a therapeutic target in the treatment of cancer.

Authors:  Alberto J Montero; Jacek Jassem
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

3.  Inflammation responsive logic gate nanoparticles for the delivery of proteins.

Authors:  Enas A Mahmoud; Jagadis Sankaranarayanan; José M Morachis; Gloria Kim; Adah Almutairi
Journal:  Bioconjug Chem       Date:  2011-07-05       Impact factor: 4.774

4.  Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: the role of glutathione.

Authors:  Heather M Brechbuhl; Remy Kachadourian; Elysia Min; Daniel Chan; Brian J Day
Journal:  Toxicol Appl Pharmacol       Date:  2011-08-10       Impact factor: 4.219

Review 5.  Development and maintenance of cancer stem cells under chronic inflammation.

Authors:  Toshihiko Tanno; William Matsui
Journal:  J Nippon Med Sch       Date:  2011       Impact factor: 0.920

6.  Selective induction of tumor cell apoptosis by a novel P450-mediated reactive oxygen species (ROS) inducer methyl 3-(4-nitrophenyl) propiolate.

Authors:  Xiaoxiao Sun; Midan Ai; Ying Wang; Shensi Shen; Yuan Gu; Yi Jin; Zuyu Zhou; Yaqiu Long; Qiang Yu
Journal:  J Biol Chem       Date:  2013-02-04       Impact factor: 5.157

Review 7.  VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation.

Authors:  Diana Fang; Eduardo N Maldonado
Journal:  Adv Cancer Res       Date:  2018-03-02       Impact factor: 6.242

8.  Synergistic antileukemic activity of carnosic acid-rich rosemary extract and the 19-nor Gemini vitamin D analogue in a mouse model of systemic acute myeloid leukemia.

Authors:  Ayelet Shabtay; Hagar Sharabani; Zeev Barvish; Michael Kafka; Doron Amichay; Joseph Levy; Yoav Sharoni; Milan R Uskokovic; George P Studzinski; Michael Danilenko
Journal:  Oncology       Date:  2008-10-14       Impact factor: 2.935

9.  Increased generation of intracellular reactive oxygen species initiates selective cytotoxicity against the MCF-7 cell line resultant from redox active combination therapy using copper-thiosemicarbazone complexes.

Authors:  Fady N Akladios; Scott D Andrew; Christopher J Parkinson
Journal:  J Biol Inorg Chem       Date:  2016-03-07       Impact factor: 3.358

Review 10.  Redox regulation in cancer: a double-edged sword with therapeutic potential.

Authors:  Asha Acharya; Ila Das; Des Chandhok; Tapas Saha
Journal:  Oxid Med Cell Longev       Date:  2010 Jan-Feb       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.